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Abstract
Background: The Opti-HER HEART trial aimed to optimize activity while minimizing cardiac risk by combining
trastuzumab, pertuzumab, and paclitaxel with non-pegylated liposomal doxorubicin in the treatment of HER2-
positive early breast cancer.
Methods: Patients with stage II–IIIB HER2-positive breast cancer received neoadjuvant trastuzumab, pertuzumab,
paclitaxel, and a non-pegylated liposomal doxorubicin every three weeks for six cycles. The primary endpoint was
cardiac safety during neoadjuvant therapy. Type A (symptomatic congestive heart failure) and B (asymptomatic
reduction of left ventricular ejection fraction) cardiac events were evaluated. Secondary endpoints included the
evaluation of the pathological complete response (pCR) rate and overall response rate, among others. As an
ad-hoc exploratory analysis, the expression of 55 breast cancer-related genes, including the PAM50 genes, was
measured in 58 baseline tumor samples and 60 surgical specimens.
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Results: Eighty-three patients were recruited. The incidence of cardiac events during neoadjuvant treatment was 2.4%.
No type A cardiac event was observed. The overall pCR rate was 56.6% (95% confidence interval (CI) 45.3–67.5%).
The HER2-enriched subtype, which represented 52.0% of all baseline samples, was associated with a higher pCR
rate compared to non-HER2-enriched tumors (83.3% vs. 46.3%; odds ratio 5.76, 95% CI 1.71–19.42). The association of
subtype with pCR was independent of known clinicopathological variables, including hormone receptor status.
Compared to baseline samples, surgical specimens showed a significant downregulation of proliferation-related genes
(MKI67 and CCNB1) and ERBB2 levels, and a significant upregulation of luminal-related (ESR1 and PGR) and immune
(CD8A) genes.
Conclusions: The combination of dual HER2 blockade with trastuzumab and pertuzumab with paclitaxel and
non-pegylated liposomal doxorubicin is associated with a low rate of cardiac events. The HER2-enriched subtype is
associated with a high rate of pCR.
Trial registration: clinicaltrials.gov, NCT01669239, Registered 20 August 2012.
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Background
Trastuzumab in combination with pertuzumab and
chemotherapy improves survival in patients with HER2-
positive metastatic breast cancer (BC) [1, 2]. In locally ad-
vanced HER2-positive BC, the addition of pertuzumab to
trastuzumab-based neoadjuvant chemotherapy (NAC) in-
creases pathological complete response (pCR) rates [3–5].
Moreover, dual HER2 blockage in combination with
chemotherapy has been recently explored in the adjuvant
setting of early-stage BC in the APHINITY trial [6]. The
addition of 1 year of adjuvant pertuzumab to standard
chemotherapy plus trastuzumab led to a 19% relative risk
reduction in invasive disease-free survival [6]. Based
on this data, dual HER2 blockade in combination with
chemotherapy is the standard of care in first-line ad-
vanced disease and will become more widely used in
early BC.
In this context, cardiac dysfunction induced by anti-
HER2-based chemotherapy needs attention [7]. In the
pivotal first-line metastatic trial that led to the approval
of trastuzumab, a New York Heart Association class III–
IV cardiac toxicity of 13% and 27% was observed with
trastuzumab in combination with paclitaxel or doxorubi-
cin/cyclophosphamide, respectively [8]. According to
this data, concomitant administration of trastuzumab
and anthracyclines is not recommended. However, re-
cent data suggests that the combination of trastuzumab
with anthracyclines might be safe. The use of liposomal
anthracyclines, such as pegylated [9] or non-pegylated
liposomal doxorubicin (NPLD) [10], have shown equal
efficacy in phase III trials compared to conventional
anthracyclines in metastatic BC patients. Their formu-
lation offers the advantages of lower specific toxicities
and, possibly, an increase in efficacy [11–16]. The data
regarding cardiotoxicity were particularly encouraging,
with a lower incidence of asymptomatic and symptom-
atic cardiac toxicity. In 2010, a systematic review on
the cardiotoxicity of different anthracycline compounds
confirmed that liposomal anthracyclines reduced the
overall risk of cardiotoxicity (relative risk 0.38; p < 0.001)
and the risk of clinical heart failure (relative risk 0.20;
p = 0.02) [17]. Furthermore, concomitant administra-
tion of neoadjuvant trastuzumab with a conventional
anthracycline [18] or trastuzumab/pertuzumab with an
anthracycline/taxane combination [4] in early BC was
found to be associated with a reduction in left ventricular
ejection fraction (LVEF) in 4.6% and 5.6% of patients,
respectively.
Thus far, no studies have assessed the combination of
trastuzumab and pertuzumab with liposomal anthracy-
clines, and therefore further elucidation of the cardiac
safety of dual HER2 blockade in combination with lipo-
somal anthracycline/taxane-based chemotherapy is re-
quired. In the Opti-HER HEART trial, we evaluated the
cardiac safety and activity following six cycles of trastu-
zumab and pertuzumab, paclitaxel, and NPLD.
Methods
Study design and participants
The Opti-HER HEART trial is an open-label, multicen-
ter, non-randomized, single-arm phase 2 study. Female
patients aged between 18 and 74 years with histologi-
cally confirmed stage II–IIIB HER2-positive BC eligible
for definitive surgery and adequate organic and cardiac
function (LVEF ≥ 55%) were enrolled. HER2-positive
was defined by the ASCO/CAP 2013 Guidelines and
confirmed according to local assessment [19]. Detailed
inclusion and exclusion criteria are provided in
Additional file 1.
Due to the lack of phase 1 data on the proposed regi-
men, the trial included a safety run-in consisting of a stage
of intensified cardiac and hematological safety monitoring
for the first 10 patients [20]. This safety monitoring in-
volved clinical evaluation, an electrocardiogram, weekly
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hematological evaluation, and LVEF assessment before
each cycle of study medication and every three months
during the adjuvant period, until completion of 12 months
from the day of the first administered study drug. LVEF
assessment was determined by echocardiogram or mul-
tiple-gated acquisition scan, using the same technique in
each patient across all the trial assessments. The
pre-planned safety interim analysis was evaluated by an
independent data monitoring committee (sponsor repre-
sentatives, investigators, plus an independent cardiology
expert), which deemed the trial safe and supported its
continuation to full recruitment. However, primary G-CSF
prophylaxis was recommended for the following 73 pa-
tients included in the trial.
All patients provided written informed consent, and
the protocol was approved by the Ethics Committees
from all participating institutions and Spanish Health
Authorities. The study was conducted in accordance
with Good Clinical Practice principles, the Declaration
of Helsinki, and all local regulations.
Procedures
Patients received six 21-day cycles of NPLD (50 mg/m2
intravenously (i.v.) on day 1), paclitaxel (80 mg/m2 i.v.
on days 1, 8, and 15), trastuzumab (4 mg/kg i.v. cycle 1 on
day 1, followed by 2 mg/kg i.v. weekly), and pertuzumab
(840 mg i.v. fixed-dose cycle 1 on day 1, followed by 420
mg fixed-dose cycle 2 on day 1 to cycle 6 on day 1) as
NAC followed by surgery. Patients who completed study
treatment or experienced intolerable toxicity underwent
surgery according to local practices. Asymptomatic LVEF
reductions were managed according to a protocol-specified
cardiac toxicity algorithm (Additional file 2: Figure S1).
After surgery, adjuvant treatment was administered as
per investigator preference, with a recommendation to
complete a total of 1 year of trastuzumab treatment.
Outcomes
The primary objective was cardiac safety of neoadjuvant
treatment assessed by incidence of New York Heart As-
sociation class III and IV heart failure (type A cardiac
events) [21] and LVEF reduction [21] (10 percentage-
points from baseline and to a value of < 50% or any ab-
solute decrease in LVEF ≥ 20%) by echocardiography or
multiple-gated acquisition scan (type B cardiac events).
LVEF assessments were conducted at screening/baseline,
within 2 days before day 1 of cycles 3 and 5 during the
neoadjuvant period, within 9 days before surgery, and
then every 3 months during the adjuvant treatment
period, for a total of 12 months.
Secondary objectives included the assessment of activ-
ity, and the overall cardiac and non-cardiac safety and
tolerability profile of the regimen up to 1 year after in-
clusion in the study. Safety was assessed according to
Common Terminology Criteria for Adverse Events ver-
sion 4.0. Activity was based on pCR rate in the breast
and lymph nodes (ypT0/is ypN0), overall response rate
by imaging per RECISTv1.1 criteria, and breast conser-
vation rate.
Gene expression
A section of the formalin-fixed paraffin-embedded breast
tissue was examined with hematoxylin and eosin stain-
ing to confirm the presence of invasive tumor cells and
to determine the minimum tumor surface area. Surgical
samples without invasive tumor cells were also profiled.
At least two 10 μm formalin-fixed paraffin-embedded
slides were used to purify total RNA using the High Pure
FFPET RNA isolation kit (Roche, Indianapolis, IN,
USA). Macrodissection was performed in baseline and
surgical samples (when needed) to avoid contamination
with normal breast tissue [22]. A minimum of ~100 ng
of total RNA was used to measure the expression of 55
BC-related genes using the nCounter platform (Nano-
string Technologies, Seattle, WA, USA), including the
50 genes of the PAM50 subtype predictor, androgen re-
ceptor, and four immune genes (CD4, CD8, PD1 and
PDL1). Data was normalized using five housekeeping
genes, and log2 transformed. Intrinsic molecular sub-
types were identified using the research-based PAM50
predictor as previously described [23].
Statistical analysis
Eighty-three patients were required to reject, with 80%
confidence, the null hypothesis that the addition of
NPLD to a neoadjuvant regimen containing paclitaxel,
trastuzumab, and pertuzumab does not increase the inci-
dence of cardiac events above the historical control [10,
24–28] of 18% (consisting of 3% symptomatic and 15%
asymptomatic events), at the 0.05 level of significance.
The intention-to-treat population included all enrolled
patients. The safety population is the subset of patients
who received at least one dose of study treatment and
have at least one safety assessment. Analysis of the pri-
mary safety outcome included the safety and intention-
to-treat population.
The association between two variables was evaluated
using Student’s t test, Pearson’s χ2 test, or Fisher’s exact
test. Odds ratio (OR) with a 95% confidence interval
(CI) were estimated using univariate and multivariable
logistic regression analyses. All statistical tests were two-
sided and considered significant when p ≤ 0.05. To iden-
tify genes differentially expressed between paired base-
line and surgical samples, a paired two-class significance
analysis of microarrays was used with a false discovery
rate (FDR) ≤ 1%. All statistical analyses were performed
using the R v3.2.3 software.
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Results
Clinicopathological characteristics
From June 2013 to January 2015, 83 patients with stage
II–IIIB HER2-positive BC and adequate cardiac function
were enrolled in 18 sites in Spain (Fig. 1). Patient charac-
teristics are summarized in Table 1. The mean age of pa-
tients was 49.5 (standard deviation, 10.9) years, with the
most frequent age group (n = 45; 54.2%) being 45–64
years of age. The mean body mass index was 26.4 kg/m2
(standard deviation, 5.9) and 21.7% were active smokers;
9.6% (n = 8) of patients were under treatment for arterial
hypertension, 4.8% (n = 4) for diabetes mellitus, and
9.6% (n = 8) for dyslipidemia. Most patients were
pre-menopausal (n = 54; 65.1%) and had hormone re-
ceptor (HR)-positive disease (n = 57; 68.7%), clinically
node-positive disease (n = 39; 46.9%), or T2 tumors
(n = 70; 84.3%); stage III disease occurred in 21.7% (n = 18)
of patients.
Treatment safety
Overall, 78 (93.9%) patients underwent surgery (Fig. 1),
of whom 72 (86.7%) completed six cycles of treatment,
and six patients stopped treatment before completion
of the six cycles due to toxicity. Overall, five patients
discontinued treatment, one (1.2%) due to objective dis-
ease progression, one (1.2%) following the first cycle
due to a paclitaxel-associated hypersensitivity reaction,
and one (1.2%) died after the first cycle due to acute re-
spiratory failure at home; no necropsy was performed.
The mean LVEF at baseline was 66% (range 57–88%).
For 27.7% (n = 23) of patients at least one LVEF assess-
ment was missing or not performed within the protocol-
specified interval. In 79.5% (n = 67) of patients, the final
treatment value (the last available LVEF value up to the
end of the study treatment period) was almost unchanged
compared with baseline (no change, or increase or de-
crease from baseline by ten percentage points).
The study met its primary endpoint with an incidence
of cardiac events during NAC of 2.4% (95% CI 0.2–
8.4%). All cardiac events were type B and occurred in
Fig. 1 CONSORT diagram
Table 1 Patient demographics at baseline
n %
83 –
Age, median and range 49 (22–78)
Tumor size, median (mm) and range 30 (20–80)
Clinical nodal status
N0 40 48.2
N1 30 36.1
N2 8 9.6
N3 1 1.2
Nx 4 4.9
Hormone receptor status
Negative 26 31.3
Positive 57 68.7
Menopausal status
Pre-menopausal 54 65.1
Post-menopausal 29 34.9
Tumor stage
II 65 78.3
III 18 21.7
Histologic grade
1 5 6.0
2 28 33.7
3 32 38.6
Unknown 18 21.7
Gavilá et al. BMC Medicine            (2019) 17:8 Page 4 of 12
two patients, with an absolute decrease in LVEF up to
45% and 38% (Fig. 2); 1 patient with a type B cardiac
event was able to receive standard adjuvant trastuzu-
mab after surgery and the second was lost to follow-up
after consent withdrawal. During adjuvant treatment
with trastuzumab, 4 further patients (5.1%, 95% CI 1.4–
12.6) presented a type B cardiac event; the LVEF value
recovered to ≥ 50% in 100% of those patients.
The most frequent grade 3–4 adverse event during
NAC was neutropenia (n = 28, 34%), which was less fre-
quent in patients receiving G-CSF prophylaxis (25% vs.
67%) and was complicated with febrile neutropenia in
five patients (6.0%). Other common adverse events were
asthenia (n = 11; 13.3%), mucositis (n = 8; 9.6%), and
diarrhea (n = 6; 7.2%). The most common of adverse
events are presented in Table 2.
Treatment activity
Forty-seven (56.6%; 95% CI 45.3–67.5%) patients achieved
a pCR in the breast and axilla. Patients with HR-negative
disease had a significantly higher overall pCR rate than
patients with HR-positive disease (76.9% vs. 47.3%, OR
3.1, 95% CI 1.2–8.7). No other clinicopathological vari-
able (i.e., age, tumor size, menopausal status, nodal sta-
tus, or histological grade) was associated with pCR. The
overall response rate was 91.3% (n = 74 of 81 evaluable
patients). Only one patient had disease progression on
study treatment and underwent a different therapy.
Mastectomy was planned in 35 patients before NAC; of
these, 4 (11.4%) patients were able to receive breast
conserving surgery after NAC.
Intrinsic subtype identification at baseline
A total of 58 (69.8%) baseline tumors were profiled
for gene expression. No statistically significant differ-
ences were observed between baseline characteristics
of this subset of samples and the overall study cohort
(Additional file 3: Table S1). The majority of tumor
samples (n = 30; 52.0%) were identified as HER2-enriched
(Fig. 3a), followed by basal-like (n = 7; 12.07%), luminal A
Fig. 2 Left ventricular ejection fraction (LVEF) changes during neoadjuvant treatment and adjuvant period: from global population in red and from each
of six patients who had > 10% drop in LVEF during the study period
Table 2 Most common adverse events
Grade 1–2 Grade 3 Grade 4
n % n % n %
Hematologic
Neutropenia 10 12.0 19 22.9 9 10.8
Anemia 24 28.9 4 4.8 0 0.0
Thrombocytopenia 1 1.2 0 0.0 0 0.0
Febrile neutropenia 0 0.0 4 4.8 1 1.2
Non-hematologic
Increased ALT concentration 1 1.2 0 0.0 0 0.0
Increased AST concentration 1 1.2 0 0.0 0 0.0
Asthenia/Fatigue 61 73.5 11 13.3 0 0.0
Nausea 46 55.4 4 4.8 0 0.0
Diarrhea 63 75.9 6 7.2 0 0.0
Vomiting 28 33.8 1 1.2 0 0.0
Mucositis 44 53.0 8 9.6 0 0.0
Peripheral edema 2 2.4 0 0.0 0 0.0
Peripheral sensory neuropathy 15 18.1 5 6.0 0 0.0
Dry skin 11 13.2 0 0.0 0 0.0
Left ventricular dysfunction 2 2.4 1 1.2 0 0.0
Gavilá et al. BMC Medicine            (2019) 17:8 Page 5 of 12
(n = 6; 10.3%), and luminal B (n = 6; 10.3%). As expected,
the intrinsic subtype differed between HR-positive (Fig. 3b)
and HR-negative (Fig. 3c) disease (p = 0.021). Of note, no
luminal tumor was identified in HR-negative disease, and
only 1 basal-like sample was identified in HR-positive dis-
ease. Interestingly, the HER2-enriched subtype was identi-
fied in 52.5% (n = 21) and 50% (n = 9) of HR-positive and
HR-negative disease, respectively.
Intrinsic subtype identification at surgery
A total of 60 (76.9%) surgical specimens were profiled
regardless of the type of pathological response (Fig. 3d).
The vast majority of samples (n = 46; 76.6%) were classi-
fied as normal-like, followed by luminal A (n = 12; 20%),
luminal B (n = 1; 1.7%), and HER2-enriched (n = 1; 1.7%).
As expected, the normal-like subtype was identified in
a higher proportion of samples achieving a pCR (89.3%)
compared to samples with residual disease (30.7%; p <
0.001) (Additional file 4: Figure S2). Five cases (12.2%) that
achieved a pCR were identified as luminal A (n = 4) and
HER2-enriched (n = 1).
Treatment activity based on baseline intrinsic subtype
Rates of pCR varied significantly according to intrinsic
subtype (p < 0.001) determined at baseline. The highest
rate of pCR was observed in the basal-like subtype
(85.7%), followed by HER2-enriched (83.3%), normal-like
(44.4%), luminal A (33.3%), and luminal B (16.6%). HER2-
enriched tumors were found to be associated with higher
pCR rates compared with non-HER2-enriched tumors
(83.3% vs. 46.5%; OR 5.7, 95% CI 1.7–19.4, p = 0.004),
even after adjusting for HR status, tumor size, age, and
nodal status (OR 13.5, 95% CI 2.5–72.5, p = 0.002).
Within HR-positive disease, the pCR rates of HER2-
enriched and non-HER2-enriched tumors were 76.1%
and 31.5%, respectively.
a b
c
e
d
Fig. 3 Molecular heterogeneity of HER2-positive breast cancer. Intrinsic subtype distribution in baseline tumors (a), according to hormonal receptor
status (b, c), and in surgical tumors (d). e Pathological complete response (pCR) rates of the intrinsic subtypes identified at baseline
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Treatment activity based on baseline single gene
expression
We evaluated the association between the expression (as
a continuous variable) of each gene measured at baseline
and pCR (Additional file 5: Figure S3). The expression of
8 and 6 genes was found significantly associated with
pCR and residual disease, respectively (FDR ≤ 1%). Among
them, amplicon 17q12-21 genes, such as ERBB2 and
GRB7, and immune genes related to CD8 T-cell infiltra-
tion, such as CD8A and PD1, were associated with a
higher likelihood of achieving a pCR. On the contrary,
luminal-related genes, such as ESR1, PGR, NAT1, and
BCL2, were associated with residual disease at surgery.
Additionally, we assessed the association of each indi-
vidual gene with pCR after adjusting for clinicopatholog-
ical parameters such as HR status, tumor size, age, and
nodal status. Eight of the 14 genes (57.1%) remained sig-
nificantly associated with pCR (Additional file 5: Figure
S3). A similar analysis was performed after adjusting for
the previous clinicopathological variables and intrinsic
subtype (HER2-enriched vs. non-HER2-enriched). Only
CD8A remained significantly associated with pCR.
Single gene expression changes between baseline and
surgery
To identify genes whose expression changed between
baseline and surgical specimens, we performed a paired
two-class significance analysis of microarrays. A total of
49 of the 55 genes (89.1%) were found to change their
expression between the two time-points (FDR ≤ 1%;
Additional file 6: Table S2). Compared to baseline sam-
ples, 36 and 13 genes were found to be under- and
overexpressed in surgical specimens, respectively. For
example, there was an increase in the expression of
both hormone receptors (i.e., ESR1 and PGR) and
CD8A, and a decrease in the expression of ERBB2 and
proliferation-related genes (Fig. 4).
Finally, we repeated the same analysis focusing on
19 surgical samples with residual disease (i.e., after ex-
cluding the samples that achieved a pCR). A total of
22 genes were found to have a significant change in
expression. Compared to baseline samples, 2 genes
(i.e., EGFR and SFRP1) were more expressed in re-
sidual tumors, and 20 genes were less expressed, in-
cluding ERBB2 and MKI67.
a b c
d e f
Fig. 4 Six differentially expressed genes between baseline and surgical specimens. a ESR1, b PGR, c ERBB2, d CD8A, e MKI67, f CCNB1
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Discussion
Results from the Opti-HER HEART trial suggest that a
regimen that includes the most active drugs for HER2-
positive disease (trastuzumab, pertuzumab, paclitaxel,
and anthracycline) is effective and is associated with a
low rate of cardiac events. Among 83 patients recruited,
no episode of symptomatic heart failure was observed,
and only 2.4% experienced an asymptomatic cardiac event
during NAC. Our results confirm that a dual blockade in
combination with anthracycline and taxanes is associated
with a low incidence of asymptomatic LVEF decline or
symptomatic heart failure [29].
Recently, four further studies have assessed the con-
current administration of trastuzumab and pertuzu-
mab with anthracyclines. In arm A of the phase 2
TRYPHAENA trial, 75 patients received six cycles of
trastuzumab and pertuzumab in combination with
5-fluorouracil, epirubicin, and cyclophosphamide (FEC)
followed by docetaxel [4]. Four (5.6%) patients experi-
enced a reduction in LVEF of ≥ 10 percentage points
from baseline to < 50%, and no patient experienced
symptomatic cardiac toxicity. During post-treatment
follow-up, 2 out of 72 (2.8%) patients had left ventricu-
lar systolic dysfunction of any grade; 8 (11.1%) patients
experienced a LVEF reduction of 10% from baseline to
< 50% [30]. In the HER2-positive cohort from the
GeparSepto trial [31], 396 patients received four cycles
of weekly paclitaxel (either solvent-based or nab-pacli-
taxel, according to randomization) followed by four cy-
cles of epirubicin plus cyclophosphamide, with
concurrent trastuzumab and pertuzumab. A LVEF re-
duction from baseline occurred in 7.6% of patients,
with 2.0% of patients showing a reduction to < 50%,
representing a ≥ 10% reduction from baseline. Foldi et
al. [32] treated 50 patients with weekly paclitaxel
followed by FEC in combination with trastuzumab and
pertuzumab. Overall, 14 of 50 patients experienced a ≥
10% reduction in LVEF during the treatment and
48-week cardiac monitoring period. Only one patient
had an LVEF reduction to below the limit of 50% [33].
In arm B of the TRAIN-2 study [32], 219 patients were
randomized to receive three cycles of FEC followed by
six cycles paclitaxel and carboplatin in combination
with trastuzumab and pertuzumab concurrent with all
chemotherapy cycles. The overall incidence of clinically
significant decline in LVEF (10 percentage points from
baseline to an absolute value below 50%) was 5%.
Regarding non-cardiac toxicities, the combination was
well tolerated; nevertheless, G-CSF administration should
be strongly considered due to high rates of grade 3–4
neutropenia without this supportive treatment. Other
adverse effects were manageable and are concordant
with those reported in the TRYPHAENA [4] and BERE-
NICE trials [34].
The pCR rate of 56.6% obtained in our study is similar
to those observed in the TRYPHAENA [4] (56.2% in
arm A), BERENICE (61.8% in cohort A) [34], and KRIS-
TINE [35] trials (56.0% in the TCH+P arm). Interest-
ingly, no difference in pCR rates was observed across
these studies despite the different proportions of HR-
positive versus HR-negative disease. The proportion of
HR-positive disease was higher in our study (68.7%) than
in the KRISTINE (62%), BERENICE (64.3% in Cohort
A), and TRYPHAENA (53.4% in Arm A) trials. The pCR
rates according to HR status were also similar across the
four studies. In HR-negative disease, the pCR rates were
76.9%, 79.4% (pCR in the breast-only group), 81.5%, and
72.4% in the Opti-HER HEART, TRYPHAENA, BERE-
NICE, and KRISTINE trials, respectively. The pCR rates
in HR-positive disease were 47.3%, 46.2% (pCR in the
breast-only group), 51.6%, and 44.0% in the Opti-HER
HEART, TRYPHAENA, BERENICE, and KRISTINE tri-
als, respectively.
To contextualize the activity results of the Opti-HER
HEART trial, we have reviewed the literature and com-
bined the results of 16 neoadjuvant HER2-positive trials
incudling a total of 2923 patients [4, 23, 34, 36–44]
(Additional file 6: Table S2). Treatment activity was
based on the type of chemotherapy (no chemotherapy,
taxane only, or anthracycline/taxane based) and of anti-
HER2 treatment (trastuzumab only or dual HER2 block-
ade). The pCR rates achieved with dual HER2 blockade
in the absence of chemotherapy (29.3%; 95% CI 23.4–
35.9) in an unselected population were comparable to
the pCR rates achieved with a 12-week treatment of a
taxane (either docetaxel or paclitaxel) in combination
with trastuzumab (34.6%; 95% CI 29.7–39.6) (Fig. 5).
The pCR rate achieved with anthracycline/taxane-based
chemotherapy in combination with trastuzumab (40.9%;
95% CI 38.4–43.4) was higher than the pCR rate following
dual HER2 blockade without chemotherapy (29.3%).
Moreover, treatment with a taxane alone in combination
with dual HER2 blockade with trastuzumab and lapatinib
or pertuzumab obtained higher pCR rates compared to
anthracycline/taxane-based chemotherapy in combin-
ation with trastuzumab (51.2% vs. 40.9%). Finally,
anthracycline/taxane-based chemotherapy in combin-
ation with dual HER2 blockade led to higher pCR rates
compared to taxane-only in combination with dual
HER2 blockade (63.5% vs. 51.2%). These results, to-
gether with those from pivotal adjuvant trial [6], sug-
gest that multi-agent chemotherapy and dual HER2
blockade should be considered the standard of care for
most patients with early-stage HER2-positive disease,
although strategies to de-escalate treatment in HER2-
positive disease, such as paclitaxel in combination with
trastuzumab, might be considered for most patients
with small node-negative disease [45, 46].
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Our study further supports that HER2-positive disease
is biologically heterogeneous and that this heterogeneity
is not completely captured by HR status [23, 47–50].
Among the different intrinsic molecular subtypes of BC,
the HER2-enriched was the most prevalent, being sig-
nificantly associated with higher pCR rates compared to
non-HER2-enriched (83.3% vs. 46.4%). Of note, the pCR
rate of the HER2-enriched subtype in our study is simi-
lar to that obtained with paclitaxel, trastuzumab, and
lapatinib in CALGB40601 (83.3% vs. 80.0%) [43], and
higher than the pCR rate obtained with lapatinib and
trastuzumab without chemotherapy in the SOLTI-PAM-
ELA trial (83.3% vs. 40.6%) [23]. These data suggest that,
in the presence of dual HER2 blockade, the HER2-
enriched subtype is still chemo-sensitive but might not
benefit from additional chemotherapy beyond just a sin-
gle taxane. Further studies are needed to define the clin-
ical utility of the intrinsic subtypes within HER2-positive
disease.
In the last few years, most studies have focused on the
intrinsic subtypes of primary untreated HER2-positive
tumors [23, 48–51]. However, less is known regarding
the subtype distribution in residual tumor samples
treated with chemotherapy and anti-HER2 therapy.
Similarly to the CALGB40601 study [43], most residual
specimens were classified as luminal A or normal-like.
Although the normal-like subtype has been associated
with lower tumor cellularity at surgery, the presence of
luminal A tumors fits with the observed increased ex-
pression of ESR1 and PGR, and decreased expression of
proliferation-related genes like CCNB1 and MKI67.
Whether this is due to changes in the biology of tumor
cells at baseline or to selection of clones by NAC cannot
be addressed herein and remains unknown. In addition,
it is unclear why five cases that achieved a pCR were
identified as non-normal subtypes.
Two interesting findings regarding immune gene ex-
pression were identified in our study. First, we observed
an association between the mRNA expression levels of
CD8A and PD1 measured at baseline and the likelihood
of achieving a pCR. CD8A provided additional informa-
tion beyond intrinsic subtype in a multivariable model.
This is concordant with findings obtained in tumor sam-
ples from the CALGB40601 [43], ACOSOG Z1041 [52],
and CHER-LOBb [53] studies using different immune-re-
lated gene expression signatures. These data suggest that
integration of intrinsic subtype with immune gene expres-
sion, or tumor-infiltrating lymphocytes [54, 55], might bet-
ter predict the probability of achieving a pCR. Second, we
observed that immune genes, such as CD8A and PD1,
were significantly upregulated in surgical specimens com-
pared to baseline samples, indicating that immune activa-
tion is a dynamic phenomenon during treatment.
A limitation of our trial is that long-term cardiac
safety was not evaluated and no survival outcome data is
available. Furthermore, given the relatively small sample
size, the number of observed events results in a lack of
precision of the estimated rate, exacerbated by the fact
that patients had a low probability of cardiac events due
to their mean age and lack of risk factors.
Fig. 5 Rates of pathological complete response (pCR) according to the type of chemotherapy and anti-HER2 therapy using data from 15 neoadjuvant
clinical trials in HER2-positive breast cancer. Bars denote 95% CIs. T taxane, L lapatinib, H herceptin (trastuzumab), A/T anthracycline/taxane based
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Moreover, the genomic correlative analyses were ex-
ploratory and did not include all specimens of the study
(69.9% baseline and 76.9% surgical specimens). Add-
itionally, a rather small number of genes was evaluated.
Therefore, we were limited regarding the ability to derive
new gene signatures and identify new biological pro-
cesses associated with treatment response. To overcome
this issue, we are currently performing RNA-seq analysis
in all samples obtained from this study.
Conclusions
The combination of trastuzumab, pertuzumab, paclitaxel,
and NPLD is associated with a low rate of cardiac events.
Among the different molecular subtypes of HER2-positive
disease, the HER2-enriched is associated with a very
high rate of pCR (~80%). Exploiting the biology of
post-treatment samples warrants further investigation.
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